APUS vs MSFT: Which Stock is Better?

Side-by-side comparison of Apimeds Pharmaceuticals Us Inc and Microsoft Corp in 2026

Comparison Updated:

APUS

Apimeds Pharmaceuticals Us Inc

$1.88

MSFT

Microsoft Corp

$422.50

Key Metrics Comparison

MetricAPUSMSFTWinner
Market Cap$23.64MN/AAPUS
P/E RatioN/A26.31MSFT
EPS (TTM)$N/A$16.07MSFT
Revenue Growth0.0%0.2%MSFT
Gross Margin0.0%68.6%MSFT

Analyze APUS

Full quant analysis

Analyze MSFT

Full quant analysis

Analyze Each Stock

Frequently Asked Questions

Is APUS or MSFT a better investment?

Comparing APUS and MSFT: Apimeds Pharmaceuticals Us Inc has a market cap of $23.64M while Microsoft Corp has N/A. Both companies have their strengths - use our detailed metrics comparison to make an informed decision.

What is the difference between APUS and MSFT?

APUS (Apimeds Pharmaceuticals Us Inc) and MSFT (Microsoft Corp) differ in valuation, growth rates, and profitability metrics. Our comparison shows which company leads in each category.

Which stock has better value: APUS or MSFT?

Based on P/E ratios, compare detailed valuation metrics on our dashboard.

Which is growing faster: APUS or MSFT?

MSFT has higher revenue growth at 0.2% vs 0.0% for APUS.

Which company is more profitable: APUS or MSFT?

Microsoft Corp (MSFT) has higher gross margins at 68.6% compared to 0.0% for APUS.

Which is the larger company: APUS or MSFT?

Apimeds Pharmaceuticals Us Inc (APUS) is larger with a market cap of $23.64M compared to N/A for MSFT.

Should I buy APUS or MSFT in 2026?

Both APUS and MSFT have investment merit. APUS trades at $1.88 while MSFT trades at $422.50. Consider your investment goals, risk tolerance, and portfolio diversification before deciding. Our AI analysis tools can provide personalized insights.

What are the key differences between APUS and MSFT stock?

Key differences: Market Cap ($23.64M vs N/A), P/E Ratio (N/A vs 26.3x), Revenue Growth (0.0% vs 0.2%), Gross Margin (0.0% vs 68.6%).

Popular Stock Comparisons